Patents by Inventor Marina Modric

Marina Modric has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF TRYPTOPHAN CATABOLISM
    Publication number: 20210238139
    Abstract: There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disorder in a patient.
    Type: Application
    Filed: May 31, 2019
    Publication date: August 5, 2021
    Applicant: E-Therapeutics PLC
    Inventors: Tanja Poljak, Marina Modric, Srinivasamurthy Vadlamudi, Colin Stubberfield
  • 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
    Patent number: 7262302
    Abstract: The present invention relates to derivatives of 1-thia-3-aza-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: August 28, 2007
    Assignee: GlaxoSmithKline Istrazivacki Centar Zagreb, D.O.O.
    Inventors: Mladen Mercep, Milan Mesic, Marina Modric, Dijana Pesic, Davor Kidemet
  • 1-Thia-3-aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
    Publication number: 20070078123
    Abstract: The present invention relates to the use of derivatives from the group of 1-thia-3-aza-dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates in a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.
    Type: Application
    Filed: November 19, 2004
    Publication date: April 5, 2007
    Applicant: PILVA-ISTRAZIVACKI INSTITUT D.O.O.
    Inventors: Mladen Mercep, Milan Mesic, Marina Modric, Dijana Pesic, Davor Kidemet
  • 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
    Publication number: 20060111340
    Abstract: The present invention relates to derivatives of 1-thia-3-aza-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Application
    Filed: May 20, 2003
    Publication date: May 25, 2006
    Inventors: Mladen Mercep, Milan Mesic, Marina Modric, Dijana Pesic, Davor Kidemet